Imaging With New Biomarker Tracks Tumor Progression, Response to Treatment for Common Brain Cancer
UT Southwestern Medical Center researchers have developed MRI-based method that can track the state and progression of a common type of genetically mutated brain cancer. The study showed that 2HG is an excellent biomarker for tracking certain gliomas with IDH mutations and also can provide a diagnosis when neurological risk from surgery is too high, researchers said. Researchers used MR spectroscopy, a method for distinguishing the chemical makeup of normal vs. mutated brain tissue, to track 2HG concentrations. “We can measure 2HG concentration and follow it during the disease course – it’s stable over long periods of time when the tumor is stable, increases when the disease progresses, and is an excellent marker of tumor response because it falls in responses to treatment that is working,” said senior author Dr. Elizabeth A. Maher, associate professor of internal medicine, neurology and neurotherapeutics. Click here to read more.
Microsurgical Approaches to Aneurysms and Skull Base Diseases 2017
Oct. 26-28, 2017; Jacksonville, Fla.
Pituitary Tumors: Diagnostic and Treatment Dilemmas
Oct. 27, 2017; New York
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
8th World Congress of Neuroendoscopy
Nov. 1-4, 2017; Cape Town, South Africa
3rd Annual Selected Topics in Craniomaxillofacial Surgery
Nov. 4, 2017 - Nov. 5, 2017; Boston, Mass.